Alkermes plc is seeing promise in the early launch metrics for its oral atypical antipsychotic combination tablet Lybalvi (olanzapine/samidorphan), and said that product combined with its established neuropsychiatric therapy portfolio gives it a differentiated commercial profile as its R&D efforts also move into oncology.
Approved by the US Food and Drug Administration last June after COVID-19-related site-inspection delays scuttled its first approval date in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?